Skip to main content

Table 1 The expression of Kir2.1 and MRP1/ABCC1 and their relationships with the clinicopathological characteristics in SCLC patients

From: Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway

Clinic pathological features

n

Expression of Kir2.1

Expression of MRP1/ABCC1

+

-

P

+

-

P

Gender

   

1

  

1

Male

43

18

25

 

21

22

 

Female

9

5

4

 

6

3

 

Age

   

0.892

  

0.426

<55†

23

7

16

 

10

13

 

≥55

29

16

13

 

17

12

 

Smoking history

   

1

  

0.328

Yes

41

20

21

 

22

19

 

No

11

3

8

 

5

6

 

Clinical stage

   

0.032

  

0.001

limited disease

25

7

18

 

6

19

 

extensive disease

27

16

11

 

21

6

 

Chemotherapy reponse

   

0.021

  

0.001

Sensitive group

25

6

19

 

7

18

 

Resistant group

22

17

5

 

20

2

 
  1. †median age.
  2. -, negative expression; +, positive expression.
  3. The P-value was calculated by χ 2 test.